# Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Source: https://onco.cc/trials/nct04342910/  
OnCo record `nct04342910` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Camrelizumab and Rivoceranib (apatinib) in gastric & gastro-oesophageal junction cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC is a phase 3 interventional study registered as NCT04342910 by Jiangsu HengRui Medicine Co., Ltd., with 550 participants planned, started 2020-09-21 and due to reach its primary completion in 2026-04-01. Interventions recorded: camrelizumab, Apatinib Mesylate, Paclitaxel and Irinotecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04342910
- Phase: 3
- Setting: A Study of Camrelizumab (SHR-1210) Combined With Apatinib Versus Paclitaxel or Irinotecan in Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Progressed After First-line Chemotherapy
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 550

## Sources

- ClinicalTrials.gov NCT04342910: https://clinicaltrials.gov/study/NCT04342910

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Rivoceranib (apatinib)](https://onco.cc/drugs/rivoceranib/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct04342910.json